Drug intelligence / Profile preview

GIP + Xenin-25 + atropine

Development stage: Unknown
Lead developer: Ulster University
Modality: Peptides, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination drug consisting of Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, and atropine. GIP is an incretin hormone that stimulates insulin secretion in a glucose-dependent manner, inhibits pancreatic beta cell apoptosis, and plays roles in bone remodeling and fat metabolism. Xenin-25 is a peptide hormone likely related to the incretin system. Atropine is an anticholinergic medication used for treating bradyarrhythmias, AV heart block, and as premedication for anesthesia. This combination may be under investigation for metabolic conditions.

Targets

mAChR (Muscarinic acetylcholine receptors)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on GIP + Xenin-25 + atropine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIP + Xenin-25 + atropine.

Explore the full profile